- Home
- PRAX vs WGS Comparison
PRAX vs WGS Comparison
Compare PRAX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | WGS |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 4.6B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | WGS |
|---|---|---|
| Price | $286.98 | $130.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $373.79 | $138.13 |
| AVG Volume (30 Days) | ★ 771.9K | 385.6K |
| Earning Date | 11-05-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $7,463,000.00 | ★ $402,190,000.00 |
| Revenue This Year | N/A | $41.17 |
| Revenue Next Year | $12,467.71 | $23.53 |
| P/E Ratio | ★ N/A | $1,799.05 |
| Revenue Growth | ★ 364.98 | 50.50 |
| 52 Week Low | $26.70 | $55.17 |
| 52 Week High | $317.72 | $170.87 |
Technical Indicators
Market Signals| Indicator | PRAX | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 36.17 |
| Support Level | $285.95 | $125.46 |
| Resistance Level | $317.72 | $143.95 |
| Average True Range (ATR) | 12.78 | 6.67 |
| MACD | -1.09 | -2.24 |
| Stochastic Oscillator | 43.76 | 15.79 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.